摘要
目的 研究人肝癌多药耐药 (MDR)的机制 ,建立HepG2多药耐药细胞系并研究其部分生物学性状。方法 应用HepG2细胞系 ,通过培养液中阿霉素 (ADM )的浓度梯度增加法 ,得到肝癌多药耐药株HepG2 /ADM。Westernblot增强化学发光法 (ECL)检测细胞株表面多药耐药基因(MDR1)的表达产物P 糖蛋白 (P 170 )、多药耐药相关蛋白 (MRP)及肺耐药蛋白 (LRP)的表达水平。结果 耐药细胞的倍增时间延长 2 .0 5倍。该耐药模型的P 170表达水平较亲本细胞升高3 .90倍 (P <0 .0 1) ,但MRP及LRP无明显变化。结论 HepG2 /ADM同其亲本细胞相比 ,其耐药性、倍增时间有明显改变 ;多药耐药性主要与MDR1的高表达有关。
Objective In order to study the multidrug resistance mechanism in primary hepatic carcinoma,to establish a multidrug resistant hepatocellular carcinoma cell line (HepG2/ADM) and investigate its biological behaviors.Methods Through exposure to gradually increased concentration of ADM,the cell line HepG2 was induced to form a multidrug resistant subcell line (HepG2/ADM).Western-blot-enhanced chemilluminesence (ECL) was used to detect the expression products of MDR1,MRP and LRP in the two cell lines.Results The doubling time of HepG2/ADM was 2.05 times longer than HepG2.The expression of p-170 in HepG2/ADM was 3.9 times more than its parent cell line.But there was no significant difference in the expressions of MRP and LRP between the two cell lines.Conclusion Compared with its parent cell line,the doubling time and multidrug resistance of HepG2/ADM had changed greatly,and its multidrug resistance was mainly correlated with a higher expression of MDR1.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2004年第5期538-540,共3页
Chinese Journal of Experimental Surgery
基金
2 0 0 1~ 2 0 0 3年卫生部临床重点学科资助项目
关键词
多药耐药基因
阿霉素
肝细胞癌
生物学
Multidrug resistance gene
ADM
Carcinoma,hepatocelluar
Biology
